BUZZ-HK-listed WuXi Biologics leads slide in pharma stocks on Merck COVID-19 pill success
BUZZ-HK-listed WuXi Biologics leads slide in pharma stocks on Merck COVID-19 pill success
** Data in a clinical trial showed Merck's antiviral pill for coronavirus could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, boosting its stock on Friday while denting shares of vaccine and coronavirus therapies makers ** Shares of WuXi Biologics 2269.HK lead slide in antibody and vaccines producers, falling 8.1% in their biggest daily percentage decline since July 26, after positive clinical trial results for Merck & Co's MRK.N experimental antiviral COVID-19 pill
*藥明生物的股價在抗體和疫苗生產商中領跌，下跌8.1%，這是自7月26日以來的最大單日百分比跌幅，此前默克公司的MRK.N實驗性抗病毒新冠肺炎片的臨牀試驗結果呈陽性
** Stock on track to snap four straight sessions of gains - biggest pct decliner on Hang Seng Index .HSI
*股票有望結束連續四個交易日的上漲-恆生指數.HSI跌幅最大
** Sino Biopharmaceutical 1177.HK drops 6.7% to HK$6.03, lowest since August 2019; the third biggest decliner on the benchmark index
*中國生物製藥1177.HK下跌6.7%，至6.03港元，為2019年8月以來的最低水平；為基準指數第三大跌幅
** Data in a clinical trial showed Merck's antiviral pill for coronavirus could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, boosting its stock on Friday while denting shares of vaccine and coronavirus therapies makers
*一項臨牀試驗的數據顯示，默克公司的冠狀病毒抗病毒藥片可以將那些最有可能感染嚴重新冠肺炎的人的死亡或住院機率減半，這在週五提振了默克的股價，同時削弱了疫苗和冠狀病毒療法制造商的股價
** Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide
*默克公司及其合作伙伴Ridgeback BioTreateutics表示，他們計劃儘快尋求美國對該藥片的緊急使用授權，並在全球範圍內進行監管申請
** In Hong Kong, Kintor Pharmaceutical 9939.HK plunges
*在香港，Kintor製藥9939.HK暴跌
26.3%, the biggest daily percentage decline since listing in May
26.3%，為5月上市以來最大單日百分比跌幅
2020
2020
** CanSino Biologics 6185.HK drops 29.5%, the worst day since listing in March 2019
*Cansino Biologics 6185.HK下跌29.5%，為2019年3月上市以來表現最差的一天
** Shanghai Fosun Pharmaceutical 2196.HK slumps 21%, the worst session since listing in October 2012
*復星醫藥2196.HK暴跌21%，為2012年10月上市以來表現最差的一個交易日
** Healthcare index .HSCIH drops 4.8%, the Hang Seng Composite Index .HSCI falls 1.8%, and Hang Seng index .HSI falls 2.2%
*醫療保健指數.HSCIH下跌4.8%，恆生綜合指數.HSCI下跌1.8%，恆生指數.HSI下跌2.2%
(Reporting by Donny Kwok)
(Donny Kuo報道)
((donny.kwok@thomsonreuters.com))
(donny.kwok@thomsonreurs.com)